Clinical Lung Cancer
@ClinicalLung
Followers
1K
Following
222
Media
122
Statuses
305
Peer-reviewed journal covering clinical and translational research of lung and other thoracic cancers published by Elsevier. EIC: Antoinette Wozniak MD
Joined March 2022
RT @StephenVLiu: How common is rebiopsy after progression on targeted therapy for NSCLC? Report @ClinicalLung included 148 pts with EGFR, A….
clinical-lung-cancer.com
Over the past several years, the demonstration of oncogene mutations in certain patients with metastatic non-small-cell lung cancers (NSCLCs) has transformed their prognoses1. The most frequent...
0
51
0
In a single-center study of NSCLC resections (2008-2020), long-term postop mortality dropped by almost 50% (HR 0.59; 95% CI 0.45–0.78) over 12 years, despite stable early post-op complications, possibly reflecting multiple contributing factors. Read more:
2
6
22
RT @tuttsakhil: Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups….
clinical-lung-cancer.com
The phase 3 CASPIAN study evaluated first-line treatment with the programmed cell death ligand-1 (PD-L1) inhibitor, durvalumab, with or without the cytotoxic T lymphocyte-associated antigen-4...
0
3
0
RT @StephenVLiu: Subgroup analyses from CASPIAN (1L platinum + etoposide + durvalumab for ES-SCLC) reported @ClinicalLung. Addition of durv….
clinical-lung-cancer.com
The phase 3 CASPIAN study evaluated first-line treatment with the programmed cell death ligand-1 (PD-L1) inhibitor, durvalumab, with or without the cytotoxic T lymphocyte-associated antigen-4...
0
18
0
RT @StephenVLiu: Real world outcomes in #BRAF NSCLC reported @ClinicalLung. 1L dabrafenib + trametinib RR 67%, PFS 13.1m compared to chemot….
clinical-lung-cancer.com
MicroabstractIn this multicenter retrospective study of 88 patients with advanced BRAF-mutant non-small cell lung cancer (NSCLC), dabrafenib plus trametinib (D+T) demonstrated superior objective...
0
24
0
RT @StephenVLiu: #ALK is a viable target even in squamous NSCLC, demonstrated by this case + review in @ClinicalLung. However, significant….
clinical-lung-cancer.com
MicroabstractThis study investigated the clinical benefit of ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-rearranged lung squamous cell carcinoma (LUSC). A patient harboring a novel...
0
28
0
RT @StephenVLiu: Retrospective report of durvalumab in pts with unresectable stage III NSCLC after chemoradiation @ClinicalLung. Compared t….
clinical-lung-cancer.com
Micro-abstractIn this multicenter retrospective study, we investigated the real-world effectiveness of durvalumab consolidation following chemoradiotherapy in patients with stage III unresectable...
0
14
0
RT @StephenVLiu: 3y f/u from Italian Phase IIIB MAURIS trial @ClinicalLung - 1L carboplatin + etoposide + atezolizumab in a broader, real-w….
clinical-lung-cancer.com
MicroabstractAtezolizumab combined to carboplatin and etoposide prolonged survival in the IMpower133 trial of untreated extensive-stage small-cell lung cancer (ES-SCLC). This end-of-study analysis...
0
10
0
RT @mtmdphd: Outcomes Following 1L Immune Checkpoint Inhibitors +/- Chemo Stratified by KRAS Mutational Status -- Real-World Analysis in Pt….
clinical-lung-cancer.com
MicroabstractKRAS mutations are the most common oncogenic driver alterations in NSCLC and influence response to immune checkpoint inhibitors. We utilized a multimodal, real world database to retros...
0
1
0
RT @StephenVLiu: Genomic landscape of resected invasive mucinous adenocarcinoma @ClinicalLung (n=107). KRAS mutations common - in 70.1% of….
clinical-lung-cancer.com
MicroabstractInvasive mucinous adenocarcinoma (IMA), a rare subtype of lung adenocarcinoma, is often driven by KRAS mutations (70.1%) or NRG1 fusions (9.2%). RNA sequencing of IMA cases with unclear...
0
18
0
RT @StephenVLiu: Real world outcomes in Japan with 1L osimertinib monotherapy in #EGFR NSCLC (OSI-FACT-OS) @ClinicalLung. With median f/u o….
clinical-lung-cancer.com
MicroabstractOsimertinib showed PFS of 20.1 months and OS of 42.0 months in EGFRm+ NSCLC, comparable to those of the FLAURA trial. Adverse events included pneumonitis (16.7%), QT prolongation (4.6%),...
0
15
0
RT @BrunaPellini: 📢🔥NEW in @ClinLungCancer:.Can chemo + anti–PD-(L)1 improve outcomes in PD-L1–negative squamous NSCLC?.Our team conducted….
0
18
0
RT @StephenVLiu: Brigatinib post crizotinib in #ALK NSCLC @ClinicalLung from @LudaBazhenovaMD. High response rates seen independent of seco….
clinical-lung-cancer.com
MicroabstractAssociations between brigatinib efficacy and ALK mutation status were examined using plasma and/or tumor tissue samples from 93 patients with crizotinib-resistant ALK-positive NSCLC in...
0
10
0
A new retrospective study suggests that EGFR exon 19 non-LRE deletions may be linked to poorer outcomes with #osimertinib, and rare exon 19 mutations (e.g., L747P, P753L) exhibit variable responses. Full article:
1
16
34
Explore a new retrospective study of patients with multiple sclerosis diagnosed with lung cancer, analyzing clinical, molecular, and survival data. Full article:
0
1
1
Immune checkpoint inhibitors have reshaped treatment for early-stage NSCLC. Read the latest article on this paradigm shift. "Immunotherapy for Early-Stage NSCLC: A Practical Guide of Current Controversies". 🔗
0
14
31
RT @SWaliany: Happy to share our study on advanced lung carcinoids w/ actionable genomic alterations (AGA).🔶2.5% of….
0
6
0
RT @HHorinouchi: 🔥 @ClinicalLung 🆙.✅ctDNA can detect minimal residual disease in curative treated NSCLC patients using a tumor agnostic app….
0
13
0